VivaBioCell
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
VivaBioCell - overview
Established
2007
Location
Udine, -, Italy
Primary Industry
Biotechnology
About
VivaBioCell is a biotechnology company pursuing the discovery and development of utilizing stem cell therapies and tissue engineering for regenerative medicine.
Current Investors
NantWorks
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy
Website
www.vivabiocell.it
Company Stage
Add-on
Total Amount Raised
Subscriber access only
VivaBioCell - timeline of key events
VivaBioCell - financials
| Fiscal Year Ended | Dec 31, 2010 | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 25,183 | 1,960 | 8,264 | 8,980 | 9,380 | 1,646,706 | 1,661,334 | 518,379 | 939,775 | 3,861,013 | 203,222 | 271,680 | - | - | - |
| % Revenue Growth (YoY) | - | (92.2%) | 321.6% | 8.7% | 4.5% | 17455.5% | 0.9% | (68.8%) | 81.3% | 310.8% | (94.7%) | 33.7% | - | - | - |
| EBITDA (USD) | (447,602) | 252,316 | (21,364) | (345,521) | 108,814 | (1,123,349) | 301,241 | 13,243 | (767,409) | 834,829 | (2,094,741) | (2,506,393) | - | - | - |
| Operating Income (USD) | (508,778) | 176,182 | (110,327) | (441,028) | 29,789 | (1,170,292) | 246,130 | (51,055) | (826,794) | 726,444 | (2,217,813) | (2,620,738) | - | - | - |
| Operating Margin | (2020.3%) | 8988.9% | (1335.0%) | (4911.2%) | 317.6% | (71.1%) | 14.8% | (9.8%) | (88.0%) | 18.8% | (1091.3%) | (964.6%) | - | - | - |
| % EBITDA Margin | (1777.4%) | 12873.3% | (258.5%) | (3847.7%) | 1160.1% | (68.2%) | 18.1% | 2.6% | (81.7%) | 21.6% | (1030.8%) | (922.6%) | - | - | - |
| NET Income (USD) | (542,482) | 57,803 | (62,546) | (468,762) | (11,889) | (894,200) | 68,562 | (130,373) | (905,291) | 614,820 | (2,209,165) | (2,656,884) | - | - | - |
| % Net Margin | (2154.2%) | 2949.1% | (756.8%) | (5220.1%) | (126.7%) | (54.3%) | 4.1% | (25.2%) | (96.3%) | 15.9% | (1087.1%) | (977.9%) | - | - | - |
VivaBioCell - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on | Completed | VivaBioCell | - |
Displaying 1 - 1 of 1
VivaBioCell - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.